CRISPR Therapeutics AG (NASDAQ: CRSP) is 2.31% higher on its value in year-to-date trading and has touched a low of $32.30 and a high of $74.00 in the current 52-week trading range. The CRSP stock was last observed hovering at around $63.93 in the last trading session, with the day’s loss setting it -1.62% off its average median price target of $80.00 for the next 12 months. It is also 40.09% off the consensus price target high of $104.00 offered by 17 analysts, but current levels are -101.0% lower than the price target low of $31.00 for the same period.
Currently trading at $62.31, the stock is 6.62% and 23.41% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.57 million and changing -2.53% at the moment leaves the stock 19.77% off its SMA200. CRSP registered 69.05% gain for a year compared to 6-month loss of -5.12%. The firm has a 50-day simple moving average (SMA 50) of $55.09 and a 200-day simple moving average (SMA200) of $55.50.
The stock witnessed a 18.64% gain in the last 1 month and extending the period to 3 months gives it a 26.03%, and is -6.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.43% over the week and 7.11% over the month.
CRISPR Therapeutics AG (CRSP) has around 304 employees, a market worth around $3.68B and $289.40M in sales. Current P/E ratio is 82.64. Profit margin for the company is 15.70%. Distance from 52-week low is 92.91% and -15.80% from its 52-week high. The company has generated returns on investments over the last 12 months (4.90%).
CRISPR Therapeutics AG (CRSP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for CRISPR Therapeutics AG (CRSP) is a “Overweight”. 17 analysts offering their recommendations for the stock have an average rating of 2.20, where 4 rate it as a Hold and 0 think it is a “Overweight”. 11 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
CRISPR Therapeutics AG is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at -$1.03 with sales reaching $14.08M over the same period.The EPS is expected to grow by 134.10% this year, but quarterly earnings will post -93.10% year-over-year. Quarterly sales are estimated to grow 257.40% in year-over-year returns.
CRISPR Therapeutics AG (CRSP) Top Institutional Holders
350 institutions hold shares in CRISPR Therapeutics AG (CRSP), with 12.78M shares held by insiders accounting for 20.94% while institutional investors hold 70.50% of the company’s shares. The shares outstanding are 60.85M, and float is at 48.24M with Short Float at 8.33%. Institutions hold 55.73% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 4.29 million shares valued at $181.75 million. The investor’s holdings represent 7.02% of the CRSP Shares outstanding. As of Mar 30, 2020, the second largest holder is Versant Venture Management, LLC with 4.21 million shares valued at $178.36 million to account for 6.89% of the shares outstanding. The other top investors are Nikko Asset Management Americas, Inc. which holds 3.77 million shares representing 6.17% and valued at over $159.74 million, while NEA Management Company, LLC holds 3.43% of the shares totaling 2.09 million with a market value of $88.67 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
A total of 17 insider transactions have happened at CRISPR Therapeutics AG (CRSP) in the last six months, with sales accounting for 12 and purchases happening 5 times. The most recent transaction is an insider sale by Ho Tony W, the company’s Executive VP, Head of R&D. SEC filings show that Ho Tony W sold 6,100 shares of the company’s common stock on May 26 at a price of $70.14 per share for a total of $0.43 million. Following the sale, the insider now owns 0.04 million shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on May 26 that Novak Rodger (President) sold a total of 36,616 shares of the company’s common stock. The trade occurred on May 26 and was made at $70.27 per share for $2.57 million. Following the transaction, the insider now directly holds 0.75 million shares of the CRSP stock.
Still, SEC filings show that on May 22, Novak Rodger (President) disposed off 13,384 shares at an average price of $70.01 for $0.94 million. The insider now directly holds 784,623 shares of CRISPR Therapeutics AG (CRSP).
CRISPR Therapeutics AG (CRSP): Who are the competitors?
The company’s main competitors (and peers) include PDL BioPharma Inc. (PDLI) that is trading 35.78% up over the past 12 months. Short interest in the company’s stock has risen 15.69% from the last report on Apr 14, 2020 to stand at a total of 3.6 million short shares sold with a short interest ratio of 4.8.